Opioid Abuse-Deterrence Labeling May Be A Long Way Off After Panel Rejects Validity Of Broad Claim
Labeling should be specific, such as a claim for injection-resistance, committee members tell FDA.
Labeling should be specific, such as a claim for injection-resistance, committee members tell FDA.